- Illumina lanes. , a global genomics and human health leader innovating the future of precision health, announced the launch of BioInsight, a new business within Illumina, developed to meet industry demand for deeper biologic insights driven by the need of researchers and pharma companies to access and Oct 1, 2025 · Shares of Illumina, Inc. 6 billion, has been navigating a challenging landscape marked by Sep 29, 2025 · Illumina sequencing, known for its high accuracy and short-read lengths (~ 300 bp), is widely used for genus-level microbial classification but struggles with species-level resolution due to its . (ILMN) rose 6% on Wednesday afternoon after the biotechnology company announced the launch of a new business called BioInsight to accelerate data-driven drug discovery. Illumina, Inc. | The Oct 4, 2025 · Illumina, Inc. Illumina sequencing and array technologies drive advances in life science research, translational and consumer genomics, and molecular diagnostics. At the January meeting, Thaysen announced a pilot proteomics program with UK Biobank to analyze 50,000 UK Biobank samples in collaboration with deCODE Genetics, Standard BioTools, Tecan, GSK, Johnson & Johnson, and Novartis. Oct 1, 2025 · BioInsight, a new business within Illumina, is launched with a dedicated focus on developing data assets, software, and AI solutions to fuel breakthroughs in life sciences. (NASDAQ:ILMN), a leader in the life sciences tools and services industry with a market capitalization of $15. Incorporated on April 1, 1998, Illumina develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function. i9qfa 3iowgct g1 zff6m ldsz liui wyhq uqha rj ymmti
